Apimeds Pharmaceuticals US, Inc. (NYSE MKT:APUS) — Stock Price
Apimeds Pharmaceuticals US, Inc. (NYSE MKT:APUS) is currently trading at $5.02 USD, down 21.44% today. Over the past 52 weeks, shares have ranged between $0.64 and $8.00. This page tracks Apimeds Pharmaceuticals US, Inc.'s live share price on the NYSE MKT exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. To see how efficiently this company converts equity into cash flow, see cash flow conversion of Apimeds Pharmaceuticals US, Inc..
Apimeds Pharmaceuticals US, Inc. (APUS) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Apimeds Pharmaceuticals US, Inc.'s daily closing share price and trading volume on the NYSE MKT exchange over the past year, giving a clear view of recent price momentum and liquidity.
Apimeds Pharmaceuticals US, Inc. Income Statement — Revenue, Profit & Earnings by Year
Apimeds Pharmaceuticals US, Inc.'s annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $5.71K | — | — | — | — |
| Gross Profit | $-5.71K | — | — | — | — |
| Research & Development | $1.63 Million | $0.00 | $98.54K | $368.00K | $489.94K |
| SG&A | $10.27 Million | $1.28 Million | $648.89K | $271.53K | $529.55K |
| Total Operating Expenses | $11.91 Million | $1.28 Million | $747.44K | $639.53K | $1.02 Million |
| Operating Income | $-11.91 Million | $-1.28 Million | $-747.44K | $-639.53K | $-1.02 Million |
| EBITDA | $-5.71 Million | $-1.27 Million | $-739.62K | $-639.53K | $-1.02 Million |
| EBIT | $-5.72 Million | — | — | — | — |
| Interest Expense | $283.01K | $117.72K | $38.07K | $29.14K | $6.74K |
| Income Before Tax | $-6.00 Million | $-1.39 Million | $-777.69K | $-668.67K | $-1.03 Million |
| Income Tax Expense | — | — | — | — | — |
| Net Income | $-6.00 Million | $-1.39 Million | $-777.69K | $-668.67K | $-1.03 Million |
Apimeds Pharmaceuticals US, Inc. Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Apimeds Pharmaceuticals US, Inc.'s financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | $164.18 Million | $13.06K | $422.08K | $6.17K | $172.17K |
| Total Current Assets | $13.98 Million | $13.06K | $422.08K | $6.17K | $172.17K |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | $2.00 Million | — | — | — | — |
| Net Receivables | — | — | — | — | — |
| Inventory | — | — | — | — | — |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | — | — | — | — | — |
| Total Liabilities | $10.84 Million | $1.37 Million | $390.20K | $719.78K | $410.65K |
| Total Current Liabilities | $10.71 Million | $1.02 Million | $123.31K | $319.78K | $10.65K |
| Long-term Debt | — | $346.84K | $266.89K | $400.00K | $400.00K |
| Net Debt | $6.12 Million | $593.39K | $-143.59K | $653.83K | $228.56K |
| Total Stockholder Equity | $153.35 Million | $-1.36 Million | $31.87K | $-713.61K | $-238.48K |
| Retained Earnings | $-10.39 Million | $-4.39 Million | $-3.00 Million | $-2.22 Million | $-1.56 Million |
Apimeds Pharmaceuticals US, Inc. Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Apimeds Pharmaceuticals US, Inc. generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | $-8.93 Million | $-733.53K | $-627.79K | $-448.17K | $-823.11K |
| Capital Expenditures | $57.33K | $0.00 | $0.00 | $0.00 | $0.00 |
| Free Cash Flow | $-8.98 Million | $-733.53K | $-627.79K | $-448.17K | $-823.11K |
| Investing Cash Flow | $-10.06 Million | — | — | — | — |
| Financing Cash Flow | $20.62 Million | $326.50K | $1.03 Million | $282.90K | $400.00K |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | $3.27 Million | $0.00 | $69.99K | $193.54K | $193.54K |
| Depreciation | $5.71K | $0.00 | — | — | — |
| Change in Cash | $9.63 Million | $-407.03K | $404.31K | $-165.27K | $-423.11K |
Apimeds Pharmaceuticals US, Inc. Earnings History — EPS Actual vs. Analyst Estimates
Track Apimeds Pharmaceuticals US, Inc.'s quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Aug 18, 2026 | — | — | — |
| Mar 31, 2026 | -22.60 | — | — |
| Dec 31, 2025 | -0.92 | — | — |
| Nov 12, 2025 | -0.14 | — | — |
| Aug 19, 2025 | -0.26 | — | — |
| Apr 15, 2025 | -0.04 | 0.00 | — |